Search
Dexamethasone
go.drugbank.com/drugs/DB01234ApprovedInvestigationalVet approved[L10695] In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms … [L10701] Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone].[A188724] Dexamethasone was granted FDA approval on 30 October 1958.
Mixtures: TOBRAMICINA E DESAMETASONE EG, TOBRAMICINA E DESAMETASONE DOC GENERICIProducts: SOLUTIO CORDES DEXA N, DEXA RHINOSPRAY N SINEChlorotrianisene
go.drugbank.com/drugs/DB00269ApprovedWithdrawnA powerful synthetic, non-steroidal estrogen. [PubChem]
International brands: Tace FNCategories: Estrogens, Non-SteroidalGallium Ga-68 gozetotide
go.drugbank.com/drugs/DB16019ApprovedInvestigational[L27006] On December 1, 2020, Ga-68 PSMA-11 was approved by the FDA as the first molecular-targeted drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) … positive lesions in men with prostate cancer.
Categories: Compounds used in a research, industrial, or household settingMethylchloroisothiazolinone
go.drugbank.com/drugs/DB14197ApprovedIt is found within many commercially available cosmetics, lotions, and makeup removers. … Methylchloroisothiazolinone (MCI) is an isothiazolinone commonly used as a preservative with antibacterial and antifungal properties.
Synonyms: 5-Chloro-N-methylisothiazolin-3-oneCategories: Compounds used in a research, industrial, or household settingRepotrectinib
go.drugbank.com/drugs/DB16826ApprovedInvestigationalThis approval is based on favorable results from the TRIDENT-1 study, where the objective response rate was 79% in TKI-naive patients and 38% in TKI-pretreated patients respectively.[L48741] … Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) specifically designed to address resistance in the treatment of non-small cell lung cancer (NSCLC), specifically due to mutations in the
Castor oil
go.drugbank.com/drugs/DB11113ApprovedNutraceuticalVet approvedCastor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. … Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation [F70].
Products: OLIO DI RICINO MARCO VITIFlotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigationaltherapy or suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. … [A259846] In May 2023, the FDA approved the use of flotufolastat F-18 for PET of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … Datopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx.
Poloxamer 188
go.drugbank.com/drugs/DB11333ApprovedP188 was originally approved by the FDA in the 1960s as a therapeutic agent to reduce viscosity in the blood before transfusions, however it is no longer available in any approved products [A27217]. … The ability of P188 in attenuating membrane damage and cell injury has been demonstrated in a variety of _in vivo_ and _in vitro_ models [A27218].
Categories: Compounds used in a research, industrial, or household settingElasomeran
go.drugbank.com/drugs/DB15654ApprovedInvestigational[L28026] A phase I, open-label, dose-ranging clinical trial (NCT04283461) was initiated in March 2020 in which 45 subjects received two intramuscular doses (on days 1 and 29). … [L39160, L39277] A similar booster dose is also available in the US for patients 18 years of age and older.